Definition and epidemiology
Bipolar II disorder is a chronic, recurrent mood disorder characterized by at least one hypomanic episode and at least one major depressive episode. Patients with Bipolar II never experience a full manic episode; if a manic episode ever occurs, the diagnosis changes to Bipolar I.
- Lifetime prevalence is approximately 0.5-1%, similar to or slightly higher than Bipolar I in some surveys.
- Mean age of onset is in the late teens to mid-20s.
- More commonly diagnosed in women than men, in contrast to a roughly equal sex distribution in Bipolar I.
- Depressive episodes are far more frequent and longer-lasting than hypomanic episodes, making the depressive pole the dominant clinical burden.
- High rates of psychiatric comorbidity, including anxiety disorders, substance use disorders, and personality disorders (especially borderline personality disorder).
- Bipolar II = hypomania + major depression; mania is NEVER present
- Hypomania: ≥4 days, no marked impairment, no psychosis, no hospitalization
- Depressive episodes dominate the course and drive most of the morbidity
- Antidepressant monotherapy risks precipitating hypomania or rapid cycling
- Quetiapine and lamotrigine have the strongest evidence for Bipolar II depression
- Lithium reduces suicide risk and is first-line for maintenance
- Lamotrigine carries a Black Box Warning for SJS/TEN; requires slow dose titration
- A subset of patients later convert to Bipolar I after a true manic episode
Etiology and risk factors
The exact cause is unknown but reflects a combination of genetic vulnerability and environmental triggers.
- Family history: first-degree relatives of patients with bipolar disorder have substantially increased risk; heritability estimates are high (around 60-80%).
- Genetic factors: polygenic risk shared in part with Bipolar I and schizophrenia; no single causative gene identified.
- Neurobiological factors: dysregulation of monoaminergic signaling (serotonin, dopamine, norepinephrine) and circadian rhythm disturbance.
- Psychosocial stressors: major life stress, sleep deprivation, postpartum period, and substance use (especially stimulants) can precipitate episodes.
- Risk factors for conversion to Bipolar I: a minority of patients with Bipolar II eventually develop a manic episode and are reclassified; this should be monitored over time.
Pathophysiology
Bipolar II shares pathophysiologic features with Bipolar I and major depressive disorder, though it is a distinct entity rather than a simple intermediate form.
- Dysregulation of neurotransmitter systems, particularly dopaminergic hyperactivity during hypomania and reduced monoaminergic tone during depression.
- Abnormalities in limbic-cortical circuits involved in mood regulation, including the amygdala, prefrontal cortex, and anterior cingulate cortex.
- Circadian rhythm and sleep-wake cycle disruption appear to play a central role, with sleep loss often triggering hypomanic switches.
- Neuroimaging studies show subtle structural and functional differences from unipolar depression, though findings are not diagnostic and are used only in research.
Clinical features
Hypomanic episode
- Elevated, expansive, or irritable mood lasting at least 4 consecutive days, present most of the day, nearly every day.
- Associated symptoms: increased self-esteem/grandiosity, decreased need for sleep, pressured speech, flight of ideas, distractibility, increased goal-directed activity, risky behavior (spending, sexual indiscretion).
- Key distinguishing feature from mania: the change in functioning is observable to others but does not cause marked impairment in social or occupational functioning, does not require hospitalization, and has no psychotic features.
Major depressive episode
- At least 2 weeks of depressed mood or anhedonia plus at least 4 additional symptoms: sleep change, appetite/weight change, fatigue, concentration difficulty, psychomotor change, feelings of worthlessness or guilt, suicidal ideation.
- Depressive episodes in Bipolar II tend to be more frequent, longer, and often more severe or atypical (hypersomnia, hyperphagia, leaden paralysis) than in unipolar depression.
- Mixed features (depressive episode with concurrent hypomanic symptoms, or vice versa) are common and increase suicide risk.
Diagnosis
Diagnosis is clinical, based on DSM-5-TR/ICD-10 criteria and longitudinal history; there is no confirmatory laboratory or imaging test.
- Requires documentation of at least one hypomanic episode AND at least one major depressive episode.
- Collateral history from family or partners is often essential, since patients frequently do not recognize hypomania as abnormal and may even value the increased energy and productivity.
- Screening tools such as the Mood Disorder Questionnaire (MDQ) can help identify possible bipolar spectrum illness but are not diagnostic alone.
- Laboratory workup (TSH, CBC, metabolic panel, urine toxicology) is used to exclude medical and substance-induced causes of mood symptoms, not to confirm the diagnosis.
- A careful history of baseline functioning, substance use, and prior antidepressant response (e.g., history of hypomania triggered by antidepressants) supports the diagnosis.
Differential diagnosis
| Condition | Distinguishing feature |
|---|---|
| Bipolar I disorder | History of a full manic episode (marked impairment, possible psychosis/hospitalization) |
| Major depressive disorder (unipolar) | No history of hypomanic or manic episodes |
| Cyclothymic disorder | Chronic fluctuating hypomanic and depressive symptoms that never meet full episode criteria, for 2+ years |
| Borderline personality disorder | Mood instability is reactive, rapid (hours), and tied to interpersonal triggers rather than sustained episodes |
| Substance/medication-induced mood disorder | Symptoms temporally linked to intoxication, withdrawal, or a specific drug (e.g., stimulants, corticosteroids) |
| ADHD | Chronic distractibility and impulsivity without discrete mood episodes or sleep changes |
| Thyroid disease (hyper/hypothyroidism) | Mood symptoms accompany systemic signs; abnormal TSH |
Management
Guidelines (APA, CANMAP, WFSBP, NICE) agree on core principles, though specific agent preference varies.
Acute depressive episode
- Quetiapine monotherapy is first-line and has the strongest evidence base for Bipolar II depression.
- Lamotrigine is widely used, particularly for depression-predominant and relapse-prevention purposes, though evidence is modest for acute depression.
- Lurasidone (alone or with lithium/valproate) is another evidence-based option in some guidelines.
- Antidepressant monotherapy is generally avoided due to risk of inducing hypomania or rapid cycling; if used, it should be combined with a mood stabilizer and monitored closely.
Hypomanic episode
- Hypomania itself often does not require aggressive pharmacologic intervention if functioning is preserved, but mood stabilizers (lithium, valproate) or atypical antipsychotics may be used, especially if symptoms are escalating or distressing.
Maintenance/relapse prevention
- Lithium remains a first-line maintenance agent, with the added benefit of reducing suicide risk.
- Lamotrigine is particularly effective for preventing depressive relapses.
- Quetiapine can be continued for maintenance in responders.
- Divalproex/valproate is an alternative mood stabilizer, used cautiously in women of childbearing potential due to teratogenicity.
Lamotrigine safety: Black Box Warning
- Lamotrigine carries a Black Box Warning for serious, potentially life-threatening skin rashes, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
- Risk is highest in the first 2-8 weeks of treatment and is increased by rapid dose titration, concomitant valproate use, and pediatric age.
- Dosing must follow a slow titration schedule per product labeling, and patients should be counseled to stop the drug and seek immediate care if a rash develops, since it is not possible to reliably predict which rashes will prove life-threatening.
Psychosocial and adjunctive measures
- Psychoeducation, cognitive-behavioral therapy, interpersonal and social rhythm therapy, and family-focused therapy improve adherence and reduce relapse.
- Sleep hygiene and regular routine help prevent mood episode triggers.
- Treat comorbid anxiety and substance use disorders concurrently, as they worsen course and treatment response.
Complications and prognosis
- Bipolar II is a chronic, relapsing illness; most patients spend significantly more time in depressive or subsyndromal depressive states than in hypomania or euthymia.
- Suicide risk is high, comparable to or exceeding that in Bipolar I, with mixed depressive episodes carrying particularly elevated risk.
- Functional impairment, primarily driven by depressive episodes, can be substantial despite the "milder" elevated-mood pole.
- Increased risk of substance use disorders, anxiety disorders, and cardiometabolic complications from both the illness and some pharmacotherapies (notably atypical antipsychotics).
- A minority of patients eventually experience a manic episode and are reclassified as Bipolar I; ongoing follow-up is important.
- Early diagnosis, consistent mood stabilizer treatment, and psychosocial support improve long-term functional outcomes.
DIGFAST for (hypo)mania: Distractibility, Irresponsibility/grandiosity, Grandiosity, Flight of ideas, Activity increase, Sleep deficit, Talkativeness/pressured speech — same symptoms as mania, just milder and shorter functional impact in Bipolar II.
Practice questions
1. A 24-year-old woman presents with a 3-week history of depressed mood, anhedonia, hypersomnia, and poor concentration. On further questioning, she describes a 6-day period two years ago when she felt unusually energetic, needed only 4 hours of sleep, talked rapidly, and completed several creative projects at work with praise from colleagues, without any impairment in functioning. She denies any history of hospitalization or psychotic symptoms. Which diagnosis best fits this presentation?
2. A 30-year-old man with Bipolar II disorder, currently in a major depressive episode, is started on fluoxetine monotherapy by his primary care physician. One week later he presents to the emergency department with his family reporting that he has been awake for three nights, is unusually talkative, and started an impulsive business venture, spending a large sum of money. He denies any psychotic symptoms and is not a danger to himself or others. What is the most likely explanation for this presentation?
3. A 28-year-old woman with known Bipolar II disorder returns for a maintenance visit. She has had three depressive episodes in the past two years and one hypomanic episode. She is currently euthymic. Which medication has the best evidence specifically for preventing future depressive relapses in this patient?
Frequently asked questions
What causes Bipolar II disorder?
Bipolar II disorder results from a combination of strong genetic predisposition and environmental triggers such as major stress, sleep deprivation, or substance use. Family history is one of the strongest risk factors, with heritability estimated at 60-80%. No single gene or definitive biological cause has been identified; it likely involves dysregulated neurotransmitter and circadian systems.
What are the first symptoms of Bipolar II disorder?
The first noticeable symptoms are usually those of a major depressive episode, such as low mood, loss of interest, fatigue, and sleep or appetite changes. Hypomanic symptoms, including elevated mood, reduced need for sleep, and increased energy, often appear later or go unrecognized since they can feel pleasant and may even boost productivity.
How is Bipolar II disorder diagnosed?
Diagnosis is clinical and requires documented history of at least one hypomanic episode and at least one major depressive episode, with no history of full mania. Clinicians rely on patient and collateral history, mental status exam, and screening questionnaires like the MDQ, while lab tests mainly rule out medical or substance-related causes.
Is Bipolar II disorder curable?
Bipolar II disorder is not curable but is highly manageable with long-term treatment. It is a chronic, relapsing condition, so the goal of treatment is to control symptoms, prevent relapse, and maintain functioning, typically through a combination of mood-stabilizing or atypical antipsychotic medication and psychotherapy.
Bipolar II vs Bipolar I — what is the difference?
The key difference is the severity of the elevated-mood episode: Bipolar I involves at least one full manic episode causing marked impairment, possible psychosis, or hospitalization, while Bipolar II involves only hypomania, a milder elevated state that does not cause severe impairment. Both involve major depressive episodes, which tend to be more frequent and prominent in Bipolar II.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: F31.8
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.